druggen-2-disease-aware-language-model-drug-discovery

name	druggen-2-disease-aware-language-model-drug-discovery
description	DrugGen-2: generative model that designs small molecules conditioned on disease ontology and target protein sequences. Fine-tuned GPT-2 with SFT + GRPO. Outperforms baselines on diabetic nephropathy targets with improved binding affinities. Use when working with drug-discovery, disease-aware, language-model.

DrugGen 2: A disease-aware language model for enhancing drug discovery

Description

Methodology from arXiv:2607.08404 (Ali Motahharynia et al., July 2026). DrugGen-2: generative model that designs small molecules conditioned on disease ontology and target protein sequences. Fine-tuned GPT-2 with SFT + GRPO. Outperforms baselines on diabetic nephropathy targets with improved binding affinities.

arXiv: 2607.08404 Categories: q-bio.QM, cs.AI, cs.LG Authors: Ali Motahharynia, Mohammadreza Ghaffarzadeh-Esfahani, Mahsa Sheikholeslami

Activation Keywords

DrugGen-2, disease-aware drug discovery, GPT-2 molecule generation, GRPO drug design, de novo drug design, disease ontology drug, diabetic nephropathy drug, molecular generation language model

Core Methodology

Problem

DrugGen-2 is a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. Developed by fine-tuning a pre-trained GPT-2 model using supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). Significantly outperformed baseline models on five protein targets relevant to diabetic nephropathy.

Key Contributions

• Novel framework addressing limitations in drug discovery
• Practical evaluation demonstrating significant improvements
• Scalable design with real-world applicability

Technical Highlights

• Architecture-preserving and efficient
• Evaluated on standard benchmarks
• Demonstrates state-of-the-art or near-SOTA performance

Implementation Guide

Step 1: Understand the Approach

# Core concept: druggen 2 disease aware language model drug discovery
# This methodology provides a framework for drug discovery
# Reference: arXiv:2607.08404
pass

Step 2: Integration Points

• Can be integrated with existing pipelines
• Modular design allows for component-level adoption
• Configuration parameters for domain-specific tuning

Step 3: Evaluation

• Benchmark on standard datasets
• Compare with baseline methods
• Measure key metrics: accuracy, efficiency, scalability

Common Pitfalls

Pitfall 1: Resource Requirements

Issue: Method may require significant computational resources. Fix: Start with smaller-scale experiments before full deployment.

Pitfall 2: Domain Transfer

Issue: Performance may vary across different domains. Fix: Validate on domain-specific data before production use.

When to Use

• When drug discovery is needed
• For applications requiring disease aware
• When standard approaches have limitations in language model

References

• arXiv:2607.08404 - "DrugGen 2: A disease-aware language model for enhancing drug discovery"
• Categories: q-bio.QM, cs.AI, cs.LG
• Published: July 2026